Table 1.
Protein | Peptide | Recognized by brain- and/or CSF-infiltrating T cells | Tolerizing activity in humans | Immuno-dominant in MS patients | High avidity recognition | Encephalitogenic (EAE) | Encephalitogenic in humanized models | References(see supplement for detailed list) |
---|---|---|---|---|---|---|---|---|
MBP | Protein | S1,S2 | ||||||
Ac 1-9 | S3-S7 | |||||||
13-31 | S3-S8 | |||||||
30-44 (p.i.) | S9, S10 | |||||||
69-86 | S4 | |||||||
79-87 | S4, S11, S12 | |||||||
83-99* (p.i.) | S9, S13-S19 | |||||||
96-109 | S4 | |||||||
110-118 | S20 | |||||||
111-129 | S8, S21, S22 | |||||||
130-144 (p.i.) | S9, S10 | |||||||
140-154 (p.i.) | S9, S10 | |||||||
146-170 | S9, S23 | |||||||
PLP | Protein | S24, S25 | ||||||
40-60 | * | S26-S29 | ||||||
56-70 | S27, S30 | |||||||
89-106 | S31-S34 | |||||||
95-117 | S31 | |||||||
139-154 | S35, S36 | |||||||
178-197 | S26, S37 | |||||||
190-208 | S25 | |||||||
184-209 | S25, S37 | |||||||
217-233 | S38 | |||||||
MOG** | Protein | S39-S45 | ||||||
1-20 | S46-S48 | |||||||
11-30 | S47 | |||||||
21-40 | S20, S49 | |||||||
31-50 | S20, S49 | |||||||
35-55 | S8, S46, S49-S51 | |||||||
63-87 | S47, S48 | |||||||
64-96 | S46, S49, S52-S56 | |||||||
97-108 | S52-S56 | |||||||
119-132 | S58, S59 | |||||||
146-154 | S56, S58 | |||||||
181-195 | S58, S59 | |||||||
186-200 | S58, S59 | |||||||
MOBP | 15-36 | S60-S62 | ||||||
21-39 | *** | S60, S63 | ||||||
37-60 | S63 | |||||||
65-86/55-77 | S61, S64 | |||||||
CNPase | Protein | S60, S65 | ||||||
343-373 | S66 | |||||||
356-388 | S66-68 | |||||||
MAG | S65, S69-S75 | |||||||
OSP/claudin 11 | S65, S76-S81 | |||||||
TSTA3**** | 51-65 | S82 Own unpublished data | ||||||
136-150 | S82 Own unpublished data | |||||||
242-251 | S82 Own unpublished data | |||||||
296-310 | S82 Own unpublished data | |||||||
RASGRP2**** | 78-87 | S83 Own unpublished data | ||||||
Transaldolase H | S84-S87 | |||||||
α-B Crystallin | S88-S95 | |||||||
Neurofascin ***** | S96-S98 | |||||||
Contactin-2/TAG-1 | S98-S100 |
green color indicates that the respective evidence has been shown, red color that it has been tested and was negative. White = not known and/or not done. For some peptides, independence of antigen processing has been documented. If this was the case, it is indicated after the amino acid number by “(p.i.)”. The table only mentions T cell antigens. Antibody targets, e.g. KIR4-1 or anoctamin-2, have been omitted. MBP, myelin basic protein; PLP, proteolipid protein; MOG, myelin oligodendrocyte glycoprotein; MOBP, myelin associated oligodendrocyte basic protein; CNPase, 2’,3’-Cyclic-nucleotide 3’-phosphodiesterase; MAG, myelin-associated glycoprotein; OSP, oligodendrocyte-specific protein; RASGRP2, Ras-guanyl releasing protein 2; TSTA3, GDP L-fucose synthase.
*Humanized TCR and A*03:01 transgenic mouse.
**Exclusive expression in the CNS debated (Pagany et al. Neurosci. Lett. 2003).
***Encephalitogenic epitope in EAE different.
****Immunodominant epitopes in part mapped, but studies ongoing.
*****Anti-neurofascin antibodies lead to axonal damage when combined with co-transfer of myelin-specific T cells.
Extensive additional information on the topic can be found reviews from group (S2, S20).